Detalhe da pesquisa
1.
Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial.
Lancet Infect Dis
; 21(10): 1383-1394, 2021 10.
Artigo
Inglês
| MEDLINE | ID: mdl-33887208